Biological therapy for psoriatic arthritis: current state and future perspectives.

IF 3.2 3区医学 Q2 RHEUMATOLOGY

Rheumatology International Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI:10.1007/s00296-024-05722-1

Dominika Boboryko, Joanna Olejnik-Wojciechowska, Magdalena Baranowska, Aleksandra Wiktoria Bratborska, Patryk Skórka, Andrzej Pawlik

引用次数: 0

Abstract

Psoriatic arthritis is a medical condition that lies at the intersection of various fields of medicine, and its therapy always requires a comprehensive, holistic approach. Biological disease-modifying antirheumatic drugs (bDMARDs) constitute an extremely effective treatment method for PsA, provided that appropriate principles for patient qualification for the drug are followed, along with subsequent monitoring of the response to treatment. Based on their mechanisms of action, four main groups of bDMARDs used in PsA can be distinguished (TNF inhibitors, IL-12/23 and IL-23 inhibitors, IL-17 inhibitors, CTLA4 agonists). Clinical trials are ongoing in search of registration for additional bDMARDs, and the tasks for doctors and scientists worldwide include patient education, increasing treatment accessibility, and optimizing its costs.

查看原文本刊更多论文

银屑病关节炎的生物疗法：现状与未来展望。

银屑病关节炎是一种处于各医学领域交叉点上的疾病，其治疗始终需要一种综合、全面的方法。生物性改变病情抗风湿药（bDMARDs）是治疗银屑病关节炎的一种极为有效的方法，但前提是必须遵循适当的原则来确定患者的用药资格，并对治疗反应进行后续监测。根据其作用机制，用于 PsA 的 bDMARDs 可分为四大类（TNF 抑制剂、IL-12/23 和 IL-23 抑制剂、IL-17 抑制剂、CTLA4 激动剂）。目前正在进行临床试验，以寻找更多的 bDMARDs 注册，全球医生和科学家的任务包括患者教育、提高治疗的可及性以及优化治疗成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology International 医学-风湿病学

CiteScore

7.30

自引率

5.00%

发文量

191

审稿时长

16. months

期刊介绍： RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology. RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.